Cleveland Clinic partners with Procter & Gamble to fight heart disease

Cleveland Clinic and Cincinnati-based Procter & Gamble (NYSE: PG) are working together to develop and commercialize a product that could aid in the fight against heart disease.

Also, as part of the work, Cleveland HeartLab, one of the most successful Clinic spinout companies, will develop a diagnostic test to measure blood levels of TMAO, or trimethylamine-N-oxide — a substance researchers believe to be an even stronger predictor of heart disease than cholesterol levels. The Clinic and P&G, meanwhile, announced an agreement to develop and ultimately commercialize an over-the-counter product that could help people manage their TMAO levels.